An evaluation is due to start on 6 September 2021 into screening babies for severe combined immunodeficiency (SCID) in England. This article explains about a separate pathway for premature babies which have been screened for SCID as part of the evaluation.
The NHS severe combined immunodeficiency (SCID) screening evaluation in England is now scheduled to start from September 2021.
The revised standards have been published and will be implemented from 1 April.
Information gained from an NHS evaluation will inform a final UK National Screening Committee recommendation on whether screening for SCID should become part of the newborn blood spot screening programme.
Members of the newborn blood spot (NBS) screening programme team had an exciting opportunity recently to present at a screening conference in Hangzhou in China. NBS programme manager Christine Cavanagh talks about the trip.
Over the past few months, we’ve consulted widely with clinical, laboratory and quality assurance colleagues to help revise the newborn blood spot screening standards.
We’ve spent the last couple of months reviewing the standards for newborn blood spot (NBS) screening and would like to invite feedback from all our stakeholders.
It’s been over a year since blood spot screening labs in England began using the same new guidelines for assessing sample quality and we’d like to update everyone on progress.
March was a busy month for the NHS Newborn Blood Spot (NBS) Screening Programme and we’re now delighted to announce the publication of some great new resources.
The newborn blood spot (NBS) screening programme aims to identify babies who have one of 9 rare but serious conditions. All babies in England are offered this screening test, ideally when they are 5 days old. The test is done …